Which Key Attributes Will Drive Physician Prescribing and Formulary Inclusion of Current and Emerging PAH Therapies? Pulmonary arterial hypertension (PAH) is a severe, progressive, debilitating…
How Will the Complex Interplay Between Efficacy, Safety, and Delivery Impact Retinal Specialists’ Preferences for and Payers’ Acceptance of Current and Emerging Therapies? Diabetic macular…
Payer and Physician Perspectives on the Role of New Biologics and Biosimilars for Moderate to Severe Inflammatory Bowel Disease Moderate to severe inflammatory bowel disease (IBD) patients who…
Where Are the Remaining Areas of Opportunity for Emerging Non-TNF Biologics and Oral Agents in the Increasingly Crowded Psoriatic Arthritis Market? The availability of tumor necrosis factor alpha…
Physician and Payer Attitudes and the Impact of the Aging Population Aging is considered a new healthcare challenge globally, and Alzheimer’s disease (AD) is one of the most debilitating…
Psoriatic arthritis (PsA) is an inflammatory joint disease that is highly comorbid with psoriasis, and characterized by pain, stiffness, and/or swelling in the joints, ligaments, and tendons. In…
Physician and Payer Perspectives as Smoking and Pollution Perils Point to Sharply Increasing COPD Incidence Chronic obstructive pulmonary disease (COPD) has become a leading case of mortality and…
TreatmentTrends®: Prostate Cancer Q2 2015 (US) is part of a series of reports that examine current trends in the management of localized to metastatic prostate cancer from the perspective of both…
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma and are a common indication for liver transplantation. The late 2013 FDA…
LaunchTrends: Cosentyx (US) is a three-wave syndicated report series that specifically tracks the introduction of Novartis’s Cosentyx (secukinumab), a potent, subcutaneous IL-17 inhibitor…
In This Underserved Arena, What Clinical Attributes Will Be Most Persuasive for Neurologists and Payers Regarding Novel Outpatient Rescue Therapies? Acute repetitive seizures (ARS)—also known as…
Amid Significant Unmet Need, What Magnitude of Efficacy and Safety Do Endocrinologists and Payers Expect of New and Emerging Therapies? The evidence demonstrating the serious physical, economic,…
What Attributes of Emerging Therapies Will Most Influence Both Physicians’ and Payers’ Decisions to Effectively Position These Biologics Against IV Belimumab? Systemic lupus erythematosus (SLE…
TreatmentTrends®: Malignant Melanoma Q2 2015 (US) is the first in a series of reports that examines current trends in the management of unresectable or metastatic malignant melanoma from the…
With the Entry of New Oral and Biological Agents, Where Are the Remaining Areas of Opportunity in an Increasingly Crowded Market? Affecting more than three million people in the major…